LONG-TERM SAFETY AND EFFICACY OF 4-WEEKLY CERTOLIZUMAB PEGOL MONOTHERAPY AND COMBINATION THERAPY IN RHEUMATOID ARTHRITIS: 5-YEAR RESULTS FROM AN OPEN-LABEL EXTENSION STUDY

被引：0

作者：

Fleischmann, R. ^{[1
]}

van Vollenhoven, R. ^{[2
]}

Vencovsky, J. ^{[3
]}

Alten, R. ^{[4
]}

Davies, O. ^{[5
]}

Stach, C. ^{[6
]}

de Longueville, M. ^{[5
]}

VanLunen, B. ^{[7
]}

Choy, E. ^{[8
]}

机构：

[1] Univ Texas SW Med Ctr Dallas, Metroplex Clin Res Ctr, Dallas, TX 75390 USA

[2] Karolinska Inst, Stockholm, Sweden

[3] Inst Rheumatol, Prague, Czech Republic

[4] Charite, Schlosspk Klin, D-13353 Berlin, Germany

[5] UCB Pharma, Brussels, Belgium

[6] UCB Pharma, Monheim, Germany

[7] UCB Pharma, Raleigh, NC USA

[8] Cardiff Univ, Sch Med, Cardiff CF10 3AX, S Glam, Wales

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 72卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：435 / 435

页数：1

共 2 条

[1] Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX [J].

Choy, Ernest ;

McKenna, Frank ;

Vencovsky, Jiri ;

Valente, Robert ;

Goel, Niti ;

VanLunen, Brenda ;

Davies, Owen ;

Stahl, Hans-Detlev ;

Alten, Rieke .

RHEUMATOLOGY, 2012, 51 (07) :1226-1234

[2] Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study [J].

Fleischmann, R. ;

Vencovsky, J. ;

van Vollenhoven, R. F. ;

Borenstein, D. ;

Box, J. ;

Coteur, G. ;

Goel, N. ;

Brezinschek, H-P ;

Innes, A. ;

Strand, V. .

ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (06) :805-811

← 1 →